Last reviewed · How we verify
Calcium & Vitamine D3
Calcium & Vitamine D3 is a Nutritional supplement / Mineral and vitamin combination Small molecule drug developed by Sanofi. It is currently FDA-approved for Calcium and vitamin D3 deficiency, Osteoporosis prevention and treatment, Hypoparathyroidism.
Calcium and Vitamin D3 work together to promote bone mineralization and maintain serum calcium levels by enhancing intestinal calcium absorption and regulating calcium-phosphate homeostasis.
Calcium and cholecalciferol (Vitamin D3) are studied for various conditions, including breast cancer, primary osteoporosis, lung diseases, vitamin D deficiency, and Colles' fracture, according to ClinicalTrials.gov. Cholecalciferol, a small molecule with a mechanism as an HMG-CoA reductase inhibitor, is classified as an inhibitor drug, according to ChEMBL.
At a glance
| Generic name | Calcium & Vitamine D3 |
|---|---|
| Sponsor | Sanofi |
| Drug class | Nutritional supplement / Mineral and vitamin combination |
| Modality | Small molecule |
| Therapeutic area | Bone Health / Musculoskeletal |
| Phase | FDA-approved |
Mechanism of action
Vitamin D3 (cholecalciferol) increases intestinal absorption of dietary calcium and promotes bone mineralization, while also regulating parathyroid hormone secretion. Calcium serves as the structural mineral that is deposited into bone matrix under the influence of vitamin D3. Together, they maintain adequate serum calcium concentrations necessary for neuromuscular function, muscle contraction, and vascular tone.
Approved indications
- Calcium and vitamin D3 deficiency
- Osteoporosis prevention and treatment
- Hypoparathyroidism
- Vitamin D deficiency
Common side effects
- Hypercalcemia
- Gastrointestinal upset (constipation, nausea)
- Kidney stone formation
Key clinical trials
- Study of Vitamin D Supplementation Tailored to Vitamin D Deficiency in Breast Cancer Patients (PHASE3)
- Vitamin D Deficiency and Effect of Its Supplementation on Interstitial Lung Diseases(ILD). (NA)
- Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary Osteoporosis (PHASE3)
- SOLID-Effect of Risedronate Sodium at Distal Radius in Colle's Fracture. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Calcium & Vitamine D3 CI brief — competitive landscape report
- Calcium & Vitamine D3 updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about Calcium & Vitamine D3
What is Calcium & Vitamine D3?
How does Calcium & Vitamine D3 work?
What is Calcium & Vitamine D3 used for?
Who makes Calcium & Vitamine D3?
What drug class is Calcium & Vitamine D3 in?
What development phase is Calcium & Vitamine D3 in?
What are the side effects of Calcium & Vitamine D3?
Related
- Drug class: All Nutritional supplement / Mineral and vitamin combination drugs
- Manufacturer: Sanofi — full pipeline
- Therapeutic area: All drugs in Bone Health / Musculoskeletal
- Indication: Drugs for Calcium and vitamin D3 deficiency
- Indication: Drugs for Osteoporosis prevention and treatment
- Indication: Drugs for Hypoparathyroidism
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing